Administration is responsible for the organizational support and fiscal oversight of all Case Comprehensive Cancer Center (Case CCC) activities based at Case Western Reserve University (CWRU) and its affiliated institutions. University Hospitals (UH) and Cleveland Clinic (CCF). As the center of operations for the Cancer Center, Administration is responsible for communicating regularly with members to disseminate opportunities for funding and scientific interactions, maintaining an integrated calendar of activities and providing a support service to implement retreats, meetings, and conferences, facilitating and managing multi-investigator grants, providing administrative support to the shared resources, and supporting post-doctoral training. A staff of 12 under the leadership of Anne Duli, MPA, Associate Director for Research Administration and Finance, directly manages over $15 million in annual cancer research support. Regular administrative meetings with UH and CCF administrators promote organizational integration for cancer research across the affiliated institutions. Topics for this group's meetings include flow of information across the consortium, developments and priorities for the Cancer Center, funding opportunities, grant oversight and reporting, clinical research topics, and improved processes for communication, funds transfer and reporting. Accomplishments for Administration include providing support for the reorganization and realignment of the scientific programs, for major initiatives such as strategic planning, developing a review process for tissue use, facilitating the applications for 7 new and renewal multidisciplinary projects, training grant renewals, over 10 applications for ARRA funding, and the successful recruitment of 8 new cancer research faculty, with 3 of them having primary appointments in the Cancer Center. Future plans include providing support for key scientific initiatives of the Cancer Center, the development of the Office of Cancer Health Disparities, partnering with the Clinical and Translational Research Collaborative to establish complementary resources, streamlining administrative inter-institutional transactions and strengthening internal management of financial information.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA043703-23
Application #
8484981
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
23
Fiscal Year
2013
Total Cost
$477,096
Indirect Cost
$174,647
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Liu, Xia; Taftaf, Rokana; Kawaguchi, Madoka et al. (2018) Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Discov :
Belur Nagaraj, Anil; Joseph, Peronne; Kovalenko, Olga et al. (2018) Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. Gynecol Oncol 151:525-532
Li, Jiayang; Gresham, Kenneth S; Mamidi, Ranganath et al. (2018) Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy. Int J Cardiol 273:168-176
Enane, Francis O; Saunthararajah, Yogen; Korc, Murray (2018) Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis 9:912
Lennon, Donald; Solchaga, Luis A; Somoza, Rodrigo A et al. (2018) Human and Rat Bone Marrow-Derived Mesenchymal Stem Cells Differ in Their Response to Fibroblast Growth Factor and Platelet-Derived Growth Factor. Tissue Eng Part A 24:1831-1843
Evans, Daniel R; Venkitachalam, Srividya; Revoredo, Leslie et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Hum Mutat 39:1092-1101

Showing the most recent 10 out of 1227 publications